Medifast

Medifast, Inc. engages in the provision of healthy living products and programs. It offers the OPTAVIA brand, a lifestyle solution centered on developing new healthy habits through smaller, foundational changes called micro-habits. The firm’s product line includes bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups. The company was founded by William Vitale in 1981 and is headquartered in Baltimore, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Medifast reports Q4 revenue decline, focuses on cost management

Medifast's Q4 2022 performance saw revenue decline but strong cost management and cash generation.
Challenges include revenue outlook for Q1 2023 and competitive landscape in weight loss and coaching markets.
Opportunities lie in capital allocation strategies, maintaining shareholder value, and adapting to market trends.
Overall, Medifast remains focused on long-term growth, financial stability, and delivering on its mission.

Medifast surpasses Q1 expectations, eyes growth amid operational tweaks

Medifast's Q1 2023 performance exceeded expectations, with a focus on revenue growth and cost control measures.
Despite challenges like decreased active coaches, the company is well-positioned with a strong financial standing and growth initiatives.
Opportunities in customer acquisition, cost-saving efforts, market expansion, and innovative solutions pave the way for future success.
Guidance for Q2 2023 reflects a strategic approach to balancing growth and profitability amidst market dynamics and operational changes.

Medifast reports Q2 revenue decline, eyes sustainable growth strategies

Medifast navigated challenges in Q2 2023 with improved operating margin and strategic market exits.
The company's focus on new growth initiatives and cost-saving measures reflects adaptability to market dynamics.
While facing revenue declines and competitive pressures, Medifast aims for sustainable growth with clear targets.
Exploration of medically supported weight loss solutions and new product lines offer avenues for future expansion.

Medifast reports resilient Q3 performance, eyes growth through diversification

Medifast's Q3 performance reflects resilience amid revenue decline, with a focus on operational efficiency and financial strength. While facing challenges in revenue and expense management, the company remains agile and proactive in exploring growth opportunities through market expansion and social responsibility initiatives.

Medifast transitions to health and wellness focus amidst revenue challenges

Medifast is navigating challenges in customer acquisition and macro factors while focusing on becoming a diversified health and wellness company.
The company's strategic collaboration with Life MD and new product offerings position it for growth.
While Q4 2023 saw a revenue decrease, Medifast's improved gross profit margin and cost-saving initiatives demonstrate operational efficiency.
Investors should monitor the impact of increased marketing spending on operating margin and EPS in the coming years.

Medifast faces revenue decline due to weight loss medication trends

Medifast's Q1 2024 performance reflects challenges in revenue and income, driven by difficulties in customer acquisition amidst weight loss medication trends.
Despite the decline, the company demonstrated operational efficiency with improved gross profit margins and cost management.
Investments in marketing and collaborations present opportunities for future growth and market expansion, signaling a strategic focus on long-term success.
Navigating market challenges while capitalizing on opportunities will be crucial for Medifast's resilience and competitiveness in the weight loss industry.

Medifast reports Q2 losses, focuses on growth strategies and cost management

Medifast's Q2 2024 performance reflects a challenging period marked by revenue and profit declines, offset by margin improvements and cost reductions.
The company's strategic initiatives aim to drive long-term growth and enhance operational efficiency amidst macroeconomic headwinds and lower coach productivity.
While facing financial setbacks, Medifast's focus on targeted advertising, product diversification, and cost management signifies a proactive stance towards future recovery and growth.

Medifast adapts to industry changes with tailored programs and innovations

Medifast's Q3 2024 performance reflected revenue and net income declines, highlighting challenges in the weight loss industry.
Despite these challenges, the company's strategic focus on tailored programs, strong financial position, and new product launches indicate a proactive approach to addressing market dynamics.
Opportunities in clinical studies, new product launches, and financial strength position Medifast for potential growth and market expansion in the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Medifast, Inc. engages in the provision of healthy living products and programs. It offers the OPTAVIA brand, a lifestyle solution centered on developing new healthy habits through smaller, foundational changes called micro-habits. The firm's product line includes bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups. The company was founded by William Vitale in 1981 and is headquartered in Baltimore, MD.

Cogent Communications Holdings

Magellan Midstream Partners

Realty Income Corp

ONEOK

Vici Properties

Dividend growth stocks often provide reliable cash flows and long-term wealth for income investors. Screening dividend stocks based on safety, growth, and consistency can be beneficial to find new opportunities important for investors. In this month's article, we highlight these five dividend stocks: Medifast, Realty Income, ONEOK, VICI Properties, and Cogent Communications Holdings.

November's 5 Dividend Growth Stocks With 5.57%+ Yields

Medifast's (MED) Q3 results reflect challenges in customer acquisition. However, cost-reduction efforts and efficiency improvements as part of the "Fuel for the Future" plan bode well.

Medifast (MED) Q3 Earnings Top Estimates, Revenues Decline Y/Y

Medifast, Inc. (NYSE:MED ) Q3 2023 Earnings Conference Call November 6, 2023 4:30 PM ET Company Participants Steven Zenker - Vice President of Investor Relations Dan Chard - Chairman and Chief Executive Officer Jim Maloney - Chief Financial Officer Conference Call Participants Linda Bolton Weiser - D.A. Davidson Jim Salera - Stephens Inc. Doug Lane - Water Tower Research Operator Greetings.

Medifast, Inc. (MED) Q3 2023 Earnings Call Transcript

BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the health and wellness company known for its habit-based and Coach-guided lifestyle solution, OPTAVIA®, today reported results for the third quarter ended September 30, 2023. Third Quarter 2023 Revenue of $235.9 million, with revenue per active earning Coach of $5,008 Independent active earning OPTAVIA Coaches of 47,100 Net income of $23.1 million Earnings per diluted share ("EPS") of $2.12 Cash, Cash Equivalents, and Investment Securities of $.

Medifast Announces Third Quarter 2023 Financial Results

Medifast's (MED) third-quarter results are likely to reflect concerns surrounding customer acquisition amid a challenging landscape. However, a focus on growth plans bodes well.

Medifast (MED) Queues for Q3 Earnings: What Awaits the Stock?

Medifast (MED) is making significant strides in its digital transformation efforts and expanding its OPTAVIA lifestyle solution to meet the increasing demand in the health and wellness market.

Medifast (MED) Poised on Expansion Initiatives Amid Cost Woes

BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the company behind the health and wellness community OPTAVIA®, will announce financial results for the third quarter ended September 30, 2023 on Monday, November 6, 2023, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, and Jim Maloney, Chief Financial Officer. The conference call is scheduled to b.

Medifast to Announce Financial Results for the Third Quarter Ended September 30, 2023

B&G Foods

Morgan Stanley

BGS, MS and MED have been added to the Zacks Rank #5 (Strong Sell) List on October 12, 2023.

New Strong Sell Stocks for October 12th

Archer-Daniels-Midland Company

Kraft Heinz

Consumer staples NYSEARCA: XLP stocks are down 6.5% from their July highs and more than 10% from the 2022 peaks and may move lower. The caveat is that the sector is trading near the bottom of a range, above critical support, and there are signs of bullish activity in the market.

Are These Consumer Staples Too Cheap for Investors To Ignore?

Armada Hoffler Properties

Bank of Nova Scotia

Canadian Imperial Bank of Commerce

Dominion Energy

Innovative Industrial Properties

Janus Henderson Group

Jackson Financial

Kinder Morgan

Altria

NewLake Capital Partners, Inc.

Philip Morris

AT&T

AT&T 5.35 % Notes 2017-01.11.66 Global

Dividend growth stocks can provide reliable cash flows and promote share price appreciation. With this piece, we are screening dividend stocks based on safety, growth, and consistency. September's top dividend growth stocks with high yields we are touching on include NewLake Capital Partners, Armada Hoffler Properties, Kinder Morgan, 3M, and Philip Morris International.

September's 5 Dividend Growth Stocks With 5.31%+ Yields

BALTIMORE , Sept. 13, 2023 /PRNewswire/ -- Medifast (NYSE: MED), the health and wellness company known for its habit-based and Coach-guided lifestyle solution  OPTAVIA®, today announced its OPTAVIA ACTIVE line is now available to Customers, following a successful pre-launch to independent OPTAVIA Coaches in July 2023.

OPTAVIA ACTIVE™ Now Available

Medifast's (MED) OPTAVIA program is a robust and adaptable solution focused on health and wellness. This holistic approach positions it for sustained long-term growth.

Medifast (MED) Gains on OPTAVIA Lifestyle Solution Strength

BALTIMORE , Sept. 7, 2023 /PRNewswire/ -- Medifast (NYSE: MED), the company behind the health and wellness community,  OPTA VIA®, today announced that its Board of Directors has declared a $1.65 quarterly cash dividend to its stockholders.

Medifast Announces Quarterly Dividend

BALTIMORE , Sept. 7, 2023 /PRNewswire/ -- Medifast (NYSE: MED), the health and wellness company known for its habit-based and Coach-guided lifestyle solution OPTAVIA ®, today released findings from a new survey designed to understand the role that "self-care" plays in consumers' pursuit of their health goals, including how they perceive and practice self-care.

Medifast Survey Finds 8 out of 10 U.S. Adults say Practicing Daily "Self-Care Habits" is a Priority

Medifast (MED) reported earnings 30 days ago. What's next for the stock?

Why Is Medifast (MED) Down 7.4% Since Last Earnings Report?

British American Tobacco

British American Tobacco and Medifast each could have solid growth ahead. Both companies' payouts appear to be viable moving forward.

Want $500 in Passive Income? 2 High-Dividend Stocks to Snap Up

Lazard

Prudential Financial

U.S. credit rating cut by Fitch, inflation trending down and the Fed raising interest rates by another 25 basis points have been the headlines since our last month's article. That being said, life and the search for attractive dividend growth stocks goes on. This month we have four familiar names and one new name that I believe is worth giving a deeper look to, despite its relatively short dividend history.

August's 5 Dividend Growth Stocks With 5.74%+ Yields

Medifast's (MED) second-quarter 2023 results reflect lower sales and earnings on reduced Coach productivity and cost inflation.

Medifast's (MED) Q2 Earnings Top Estimates, Sales Decline Y/Y

Medifast (MED) came out with quarterly earnings of $2.77 per share, beating the Zacks Consensus Estimate of $1.44 per share. This compares to earnings of $3.87 per share a year ago.

Medifast (MED) Q2 Earnings and Revenues Surpass Estimates

Medifast, Inc. (NYSE:MED ) Q2 2023 Earnings Conference Call August 7, 2023 4:30 PM ET Company Participants Steve Zenker - VP of IR Dan Chard - Chairman and CEO Jim Maloney - CFO Conference Call Participants Linda Bolton-Weiser - D.A. Davidson Operator Good afternoon, and welcome to the Medifast Second Quarter 2023 Earnings Conference Call.

Medifast, Inc. (MED) Q2 2023 Earnings Call Transcript

BALTIMORE, Aug. 7, 2023 /PRNewswire/ -- Medifast (NYSE: MED), the health and wellness company known for its habit-based and Coach-guided lifestyle solution,  OPTA VIA® , today reported results for the second quarter ended June 30, 2023. Second  Quarter 2023 Revenue of $296.2 million, with revenue per active earning coach of $5,578 Independent active earning OPTAVIA Coaches of 53,100 Net income of $30.3 million Earnings per diluted share ("EPS) of $2.77 Cash and Cash Equivalents of $147.4 million and no interest-bearing debt "We are ahead of our Fuel for the Future plan with key initiatives aimed at driving efficiency and cost reduction, which helped to mitigate the impact of continued economic headwinds on our revenues during the quarter," said Dan Chard, Chairman & Chief Executive Officer of Medifast.

Medifast Announces Second Quarter 2023 Financial Results

Medifast has seen a significant decline in its stock price and market cap in the past 2 years, reflecting investors' pessimism towards the company. The stock's underperformance may be attributed to inflationary pressures and concerns over new weight loss drugs from pharmaceutical giants Novo Nordisk and Eli Lilly. Concerns over weight loss drugs are overblown and the drugs could in fact be complementary to MED's offering.

Medifast: Take Advantage Of Pessimism Over Weight Loss Drugs

Medifast's (MED) second-quarter 2023 performance will likely reflect challenges related to customer acquisition and higher cost inflation.

Medifast (MED) Queued for Q2 Earnings: Things to Consider

BALTIMORE , July 27, 2023 /PRNewswire/ -- Medifast (NYSE: MED), the health and wellness company known for its habit-based and Coach-guided lifestyle solution  OPTAVIA® , today unveiled a new product line, OPTAVIA ACTIVE. The line includes premium exercise supplements and protein powders, OPTAVIA ACTIVE Essential Amino Acid (EAAs) Blend and OPTAVIA ACTIVE Whey Protein, with other products expected to be rolled out next year.

Medifast Expands into $30B Sports Nutrition Category with OPTAVIA ACTIVE™

BALTIMORE , July 24, 2023 /PRNewswire/ -- Medifast (NYSE: MED), the company behind the health and wellness community OPTA VIA ®, will announce financial results for the second quarter ended June 30, 2023 on Monday, August 7, 2023, after market close. The Company will host a conference call to discuss the results with additional comments and details.

News for Medifast Stock (MED)